Cancer Cancer Systems Biology Metabolomics

Journal

iScience
ISSN: 2589-0042
Titre abrégé: iScience
Pays: United States
ID NLM: 101724038

Informations de publication

Date de publication:
21 May 2021
Historique:
received: 05 10 2020
revised: 22 02 2021
accepted: 09 04 2021
entrez: 26 5 2021
pubmed: 27 5 2021
medline: 27 5 2021
Statut: epublish

Résumé

Elucidations of the factors that promote the growth of disseminated tumor cells (DTCs) into life-threatening lesions stand to provide much needed prognostic and therapeutic targets of translational utility for patients with metastatic cancer. To identify such regulators, we conducted gain-of-function cDNA library screening to discover genes that foster prostate cancer cell colonization of mouse lungs as an experimental model. Our efforts identified the metabolic enzyme aldolase A (ALDOA) as a driver of cancer cell motility, anchorage-independent growth, and metastatic colonization, and as a prognosticator of adverse patient outcome across many malignancies, including prostate, breast, pancreatic, and liver cancers. Metabolomics coupled with biochemical and functional analyses revealed that ALDOA triggered the activation of adenosine-5'-monophosphate (AMP)-activated protein kinase (AMPK), which we demonstrate played essential promalignant activities in ALDOA-expressing cells. Collectively, these findings unveiled vivo approaches to identify metastatic colonization regulators and uncovered previously undescribed roles for ALDOA-AMPK pathway in tumor progression.

Identifiants

pubmed: 34036247
doi: 10.1016/j.isci.2021.102425
pii: S2589-0042(21)00393-X
pmc: PMC8138724
doi:

Types de publication

Journal Article

Langues

eng

Pagination

102425

Subventions

Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA207322
Pays : United States
Organisme : NCI NIH HHS
ID : R37 CA251543
Pays : United States

Informations de copyright

© 2021 The Author(s).

Déclaration de conflit d'intérêts

The authors declare no competing interests.

Références

Nat Med. 2010 Jan;16(1):116-22
pubmed: 20023634
Cancer Lett. 2015 Jan 28;356(2 Pt A):165-70
pubmed: 24486219
Nat Rev Cancer. 2016 Apr;16(4):201-18
pubmed: 27009393
J Clin Invest. 2010 Jun;120(6):2094-108
pubmed: 20458142
Mol Carcinog. 2014 Feb;53(2):138-44
pubmed: 22949271
PLoS One. 2014 Jan 23;9(1):e85804
pubmed: 24465716
Int J Oncol. 2017 Feb;50(2):525-534
pubmed: 28000858
Biochem Biophys Res Commun. 2018 Mar 4;497(2):639-645
pubmed: 29453983
Nature. 2004 Feb 26;427(6977):848-53
pubmed: 14985764
Semin Cancer Biol. 2002 Jun;12(3):219-29
pubmed: 12083852
Cancer Lett. 2020 Jan 28;469:481-489
pubmed: 31738958
Head Neck. 2013 Oct;35(10):1475-81
pubmed: 22987617
Adv Exp Med Biol. 2019;1210:171-184
pubmed: 31900910
Cell. 2013 Nov 7;155(4):750-64
pubmed: 24209616
Mol Cell. 2018 Jan 4;69(1):87-99.e7
pubmed: 29249655
Trends Cancer. 2015 Sep;1(1):76-91
pubmed: 28741564
Nat Rev Drug Discov. 2019 Jul;18(7):527-551
pubmed: 30867601
Cell Stem Cell. 2015 Nov 5;17(5):585-96
pubmed: 26440282
Ther Clin Risk Manag. 2017 Feb 27;13:279-285
pubmed: 28280347
Curr Opin Cell Biol. 2016 Apr;39:69-76
pubmed: 26921697
Cancer Res. 2013 May 15;73(10):2929-35
pubmed: 23644529
Oncol Rep. 2014 Nov;32(5):2031-7
pubmed: 25215901
Eur Respir J. 2011 Jun;37(6):1453-65
pubmed: 20884743
Semin Cancer Biol. 2012 Jun;22(3):234-49
pubmed: 22484561
Cell Metab. 2016 Apr 12;23(4):649-62
pubmed: 27076078
CA Cancer J Clin. 2020 Jan;70(1):7-30
pubmed: 31912902
Cell Metab. 2018 Feb 6;27(2):299-313
pubmed: 29153408
Prostate. 2009 Dec 1;69(16):1781-9
pubmed: 19676095
Cell Metab. 2013 Oct 1;18(4):546-55
pubmed: 24093678
Nature. 2012 May 09;485(7400):661-5
pubmed: 22660331
Mol Cell. 2017 Jun 15;66(6):789-800
pubmed: 28622524
Adv Mater. 2019 Dec;31(49):e1904156
pubmed: 31566275
J Biol Chem. 2002 Feb 22;277(8):6567-72
pubmed: 11748239
Oncogene. 2000 Jul 6;19(29):3330-4
pubmed: 10918589
Nat Cell Biol. 2018 Dec;20(12):1370-1377
pubmed: 30397314
Nature. 2001 Nov 8;414(6860):225-9
pubmed: 11700562
Nature. 2017 Aug 3;548(7665):112-116
pubmed: 28723898
Cancer Lett. 2020 May 28;478:82-92
pubmed: 32171858
Curr Protein Pept Sci. 2012 Mar;13(2):117-23
pubmed: 22044153
J Biol Chem. 2010 Nov 12;285(46):35505-18
pubmed: 20837469
Exp Cell Res. 2019 Jun 1;379(1):30-47
pubmed: 30894280
Oncogene. 2004 Jun 3;23(26):4641-5
pubmed: 15064711
Cell Metab. 2014 Sep 2;20(3):526-40
pubmed: 25002183
FASEB J. 2018 Jul;32(7):3924-3935
pubmed: 29505302
Oncogene. 2013 Oct 10;32(41):4932-40
pubmed: 23160380
Cancer Cell. 2013 Oct 14;24(4):410-21
pubmed: 24135279
PLoS One. 2014 Nov 07;9(11):e110736
pubmed: 25379943

Auteurs

Zhenbo Tu (Z)

Department of Pathology and Cancer Center, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.

Shengqi Hou (S)

Human Oncology and Pathogenesis Program and Department of Medicine, Memorial Sloan Kettering Cancer Center, New York 10065, USA.

Yurong Zheng (Y)

Department of Pathology and Cancer Center, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.

Maerjianghan Abuduli (M)

Department of Pathology and Cancer Center, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.

Tamer Onder (T)

Department of Molecular Biology and Genetics, School of Medicine, Koç University, Istanbul 34450, Turkey.

Andrew M Intlekofer (AM)

Human Oncology and Pathogenesis Program and Department of Medicine, Memorial Sloan Kettering Cancer Center, New York 10065, USA.

Antoine E Karnoub (AE)

Department of Pathology and Cancer Center, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.
Harvard Stem Cell Institute, Cambridge, MA 02138, USA.
Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA.

Classifications MeSH